Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jyothi Kallu"'
Autor:
Jasmine N. Tutol, Sheena D'Arcy, Kierstin M Page, Regina A. Baglia, Steven O. Nielsen, Sheel C. Dodani, Jyothi Kallu, Koushambi Mitra, Sriharika Gottipolu, Kira R Mills, Darby Ball
Publikováno v:
Rsc Chemical Biology
Human phenol sulfotransferases mediate the transfer of a sulfuryl moiety from the activated sulfate donor PAPS to hydroxy-containing substrates, altering substrate solubility and charge to affect phase II metabolism and cell signaling. Here, we prese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd675c07fbaadcd5e7a29045027f3e2
https://doi.org/10.26434/chemrxiv.13215167.v1
https://doi.org/10.26434/chemrxiv.13215167.v1
Autor:
Jyothi Kallu, Christina Fletcher, Saloni Darji, Tuhina Banerjee, Shoukath Sulthana, Nikolay Gerasimchuk, Ryan Higginbotham, Santimukul Santra
Publikováno v:
Nanotheranostics
Purpose: K-RAS is the most common mutated oncogene associated with Non-Small-Cell Lung Cancer (NSCLC). So far, there are no promising chemotherapies for the direct inhibition of K-RAS, and considered to be undruggable. In this work, we have introduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f18fb06233ce3232c008143b55fed2
https://pubmed.ncbi.nlm.nih.gov/30899640
https://pubmed.ncbi.nlm.nih.gov/30899640
Autor:
Blaze Heckert, Sudershini Reddy Vuppala, Shuguftha Naz, Shoukath Sulthana, Tuhina Banerjee, Jyothi Kallu, Tyler Shelby, Olivia Yambem, Santimukul Santra
Publikováno v:
Molecular pharmaceutics. 14(3)
K-RAS driven non-small-cell lung cancer (NSCLC) represents a major cause of death among smokers. Recently, nanotechnology has introduced novel avenues for the diagnosis and personalized treatment options for cancer. Herein, we report a novel, multifu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4add06c1e5bff9836ba396b29e38373a
https://pubmed.ncbi.nlm.nih.gov/28081601
https://pubmed.ncbi.nlm.nih.gov/28081601